All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Circuit lifetime with citrate versus heparin in pediatric continuous venovenous hemodialysis

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F16%3AE0105564" target="_blank" >RIV/00843989:_____/16:E0105564 - isvavai.cz</a>

  • Result on the web

    <a href="http://dx.doi.org/10.1097/PCC.0000000000000860" target="_blank" >http://dx.doi.org/10.1097/PCC.0000000000000860</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1097/PCC.0000000000000860" target="_blank" >10.1097/PCC.0000000000000860</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Circuit lifetime with citrate versus heparin in pediatric continuous venovenous hemodialysis

  • Original language description

    OBJECTIVES: To determine if there is a difference between regional citrate and global heparinized anticoagulation on circuit lifetimes during continuous venovenous hemodialysis in children. DESIGN: Prospective "cross-over" trial. SETTING: PICU, Department of Pediatrics, University Hospital Ostrava. PATIENTS: Children 0-18 years old. INTERVENTIONS: From 2009 to 2014, 63 eligible children (age, 89.24?±?62.9 mo; weight, 30.37?±?20.62?kg) received at least 24 hours of continuous venovenous hemodialysis. Each child received four continuous venovenous hemodialysis circuits with anticoagulants in the following order: heparin, citrate, heparin, citrate. Circuit life ended when transmembrane pressure was greater than or equal to 250?mm Hg for more than 60 minutes. MEASUREMENTS AND MAIN RESULTS: The total mean circuit lifetime was 39.75?±?10.73 hours. Citrate had a significantly longer median circuit lifetime (41.0?hr; CI, 37.6-44.4) than heparin (36.0?hr; CI, 35.4-36.6; p = 0.0001). Mortality was 33.33%. Circuit lifetime was significantly correlated to patient age (r = 0.606), weight (r = 0.763), and blood flow rate (r = 0.697). Transfusion rates (units of red cells per circuit of continuous venovenous hemodialysis) were 0.17 (0.0-1.0) with citrate and 0.36 (0.0-2.0) with heparin (p = 0.002). CONCLUSIONS: We showed in our study that citrate provided significantly longer circuit lifetimes than heparin for continuous venovenous hemodialysis in children. Citrate was superior to heparin for the transfusion requirements. Citrate was feasible and safe in children and infants.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

  • CEP classification

    FG - Paediatrics

  • OECD FORD branch

Result continuities

  • Project

  • Continuities

    V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Others

  • Publication year

    2016

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Pediatric critical care medicine

  • ISSN

    1947-3893

  • e-ISSN

  • Volume of the periodical

    17

  • Issue of the periodical within the volume

    n. 9

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    7

  • Pages from-to

    "e399"-"e405"

  • UT code for WoS article

  • EID of the result in the Scopus database